Flecainide Interactions

Co-administration contraindicated due to potential for cardiac arrhythmias.

Source: NLP:nirmatrelvir and ritonavir

Class I antiarrhythmic. Amiodarone inhibits flecainide metabolism. Reserve concomitant use; initiate at lower dose and reduce previous dose by 30-50%.

Source: NLP:amiodarone hydrochloride

Flecainide inhibits cytochrome P450 2D6, potentially causing toxic amitriptyline levels; may require lower amitriptyline doses.

Source: NLP:amitriptyline hydrochloride

CYP2D6 substrate with narrow therapeutic index. Dose adjustment likely required due to cinacalcet's strong CYP2D6 inhibition.

Source: NLP:cinacalcet

Type 1C antiarrhythmic that inhibits P450 2D6 and may increase clomipramine plasma levels, potentially causing toxicity.

Source: NLP:clomipramine hydrochloride

Type IC antiarrhythmic that inhibits P450 2D6; may increase desipramine concentrations and toxicity risk; dose adjustment may be needed.

Source: NLP:desipramine hydrochloride

Type 1C antiarrhythmic that inhibits cytochrome P450 2D6, increasing imipramine plasma concentration. May require dose adjustment and TCA plasma level monitoring.

Source: NLP:imipramine hydrochloride

Type 1C antiarrhythmic that inhibits P450 2D6, potentially increasing nortriptyline plasma concentrations to toxic levels.

Source: NLP:nortriptyline hydrochloride

CYP2D6 substrate Type 1C antiarrhythmic. Bupropion inhibits CYP2D6, increasing flecainide exposure. Dose reduction may be necessary.

Source: NLP:bupropion hcl er (xl)

CYP2D6-metabolized Type 1C antiarrhythmic. Bupropion inhibits CYP2D6 and can increase flecainide concentrations. Consider dose reduction.

Source: NLP:bupropion hydrochloride

Darifenacin may increase flecainide exposure as it is metabolized by CYP2D6 with narrow therapeutic window. Caution should be taken when used concomitantly.

Source: NLP:darifenacin

Caution when used concomitantly; darifenacin may increase exposure of flecainide, a CYP2D6 substrate with narrow therapeutic window.

Source: NLP:darifenacin hydrobromide

Type 1C antiarrhythmic that inhibits cytochrome P450 2D6, which may increase doxepin plasma concentrations. Concomitant use may require lower doses and monitoring.

Source: NLP:doxepin hydrochloride

Amiodarone inhibits metabolism of flecainide; reduce dose and monitor carefully.

Source: NLP:nexterone (amiodarone hci)

Paroxetine inhibits CYP2D6, increasing flecainide exposure. Decrease flecainide dosage if needed with concomitant paroxetine use.

Source: NLP:paroxetine

Paroxetine inhibits CYP2D6, increasing exposure of flecainide. Dosage reduction may be needed.

Source: NLP:paroxetine hydrochloride

Flecainide is predominantly metabolized by CYP450 2D6. Coadministration requires careful monitoring and may require dose reduction.

Source: NLP:terbinafine

Terbinafine inhibits CYP450 2D6, the primary metabolic pathway for flecainide. Careful monitoring and dose reduction may be required.

Source: NLP:terbinafine hydrochloride

Flecainide is predominantly metabolized by CYP450 2D6; terbinafine inhibition may increase exposure. Careful monitoring and dose reduction may be required.

Source: NLP:terbinafine tablets 250 mg

Flecainide inhibits cytochrome P450 2D6, increasing trimipramine maleate plasma concentrations and risk of toxicity.

Source: NLP:trimipramine maleate

Potential for drug-drug interaction due to possible competition for active tubular secretion via base-secreting system.

Source: NLP:midodrine hydrochloride

Too little experience with co-administration of flecainide with nifedipine to recommend concomitant use.

Source: NLP:nifedipine